Abstract: [OBJECT] The present invention aims to provide suitable workability of an envelope-shaped separator for a lead-acid battery. [SOLVING MEANS] Provided is a separator for a flooded lead-acid battery, the separator including a porous base part, side end parts arranged on width direction ends of the porous base part, and a central part interposed by the side end parts, wherein a first rib is arranged in the central part and second ribs are arranged in the side end parts, the first rib has a rib height greater than that of the second ribs, the ratio of the width (U) between both upper end parts to the rib height (H) of a rib width direction cross-section of the second ribs is 0.08 to 5.50 and the ratio of the width(S) between both lower end parts to the rib height (H) thereof is 0.13 to 6.50, the second ribs have radii of curvature (1, 2) at both upper end parts and both lower end parts of the rib width direction cross-section, and the radii of curvature (1, 2) are in the range of 0.005 to 0.350 mm.

Abstract: Methods for determining treatments for cancer patients are disclosed.

Abstract: A fusion protein comprises a nanocage monomer; and an antibody or fragment thereof linked to the nanocage monomer, the antibody or fragment thereof comprising a first member of a binding pair; wherein a plurality of the fusion proteins self-assemble to form a nanocage in which a plurality of the antibodies or fragments thereof decorate the exterior surface of the nanocage, whereby the first member of the binding pair is exposed for interacting with a second member of a binding pair.

Abstract: The present invention relates, in part, to methods for using STING agonists to polarize pro-tumor macrophages in a subject with cancer into anti-tumor macrophages, for example to improve effectiveness of PARP inhibition.

Abstract: Provided herein are crystalline Forms (or polymorphs) I, II, III, IV, V, VI, and VII of N-(5-((4-(1H-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide tosylate salt and methods of inhibiting the activity of EGFR or treating a disease mediated by EGFR by using an effective amount of at least one crystalline form described herein.

Abstract: The invention provides novel phosphoinositide 3 kinase beta-selective inhibitors and pharmaceutical compositions thereof, as well as methods of their preparation and use, in therapy of various diseases and conditions, such as solid tumors.

Abstract: The present invention is based, in part, on cancer vaccine compositions that comprise PTEN- and p53-deficient cancer cells with activated TGF?-Smad/p63 signaling pathway, and methods for using same to prevent and/or treat cancer.

Abstract: The present invention is based, in part, on the identification of novel FI.3K-mTORCI-S6K 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.

Abstract: The present invention relates to methods of treating brain metastases using synergistic combinations of anti-PI3K and anti-mTOR therapies. It has also been determined that blocking PI3K and mTOR provides therapeutic benefit for treating brain metastases.

Abstract: The present invention provides methods for measuring translation rates of RNA associated with a ribosome (e.g., mRNA) in a rapid, cost-effective, and targeted manner.

Abstract: The present invention relates to use of pyrimido-diazepinone compounds that are able to modulate protein kinases such as PI3K-? and PI3K-?, which are members of the Class I Type IA and Class I Type IB family of phosphatidylinositol-4,5-bisphosphate 3-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.

Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.

Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.

Abstract: Provided herein are small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK) having the structure of formula (I), wherein X and R1-R3 are defined in the specification. The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.

Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g.

Abstract: The present invention provides a cancer vaccine comprising DNA repair-deficient cancer cells, wherein the cancer cells are contacted with a PARP inhibitor to induce DNA breaks. In another aspect, a method of treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of a cancer vaccine comprising DNA repair-deficient cancer cells, wherein the cancer cells are contacted with a PARP inhibitor to induce DNA breaks, is provided. The present invention also provides a kit comprising DNA repair-deficient cancer cells modified as described herein, PARP inhibitors, immune checkpoint inhibitors, and combinations thereof, packaged in a suitable container.

Abstract: The present invention is based, in part, on methods for modulating regulatory T cells and immune responses using CDK4/6 inhibitors.

Abstract: Provided herein are tricyclic small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK). The compounds are useful for treating cancer and other conditions or diseases associated with aberrant MELK expression. Also provided herein are pharmaceutical compositions comprising a tricyclic compound of the invention and a pharmaceutically acceptable carrier. The invention also provides methods of treating cancers associated with over-expression of MELK.

Abstract: The present invention relates to methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents.

Abstract: Aspects of the disclosure provide fusion proteins that bind cells expressing one or more target molecules including, for example, one or more cell surface multisubunit signaling receptors (e.g.